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INTRODUCTION 
The most significant upper respiratory tract infections 
(URTIs) are sinusitis, otitis media and pharyngitis. 
All three are frequent causes of morbidity, especially 
chronic sinusitis in adults and otitis media in children. 
The need for knowledge of the causative pathogens and 
of evolving drug resistance patterns is the framework 
on which appropriate treatment decisions can be made 
and the focus of this paper. 
SINUSITIS 
Sinusitis, an infection of the mucosal lining of the 
paranasal sinuses, is an important and conmon cause of 
morbidity that afflicts more than 31 million people and 
accounts for 16 million outpatient visits per annum in 
the USA alone [I]. Occasionally, sinusitis can have a 
coniplicated course, with extension of the infection 
beyond the sinus cavity, leading to complications such 
as subdural abscess, brain abscess, meningitis, and 
orbital cellulitis [l]. It is classically divided into acute 
and chronic disease, depending on the duration of 
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symptoms. Acute sinusitis has an average duration of 
less than 3 weeks, while chronic sinusitis is present for 
at least 3 months [2]. 
ACUTE SINUSITIS 
Definition and diagnosis 
Acute sinusitis in children manifegts as two distinct 
presentations. The first is an acute, febrile illness with 
facial swelling and, sometimes, eye puffiness. The 
second type is more benign, consisting of a failure to 
get better with persistent, purulent nasal discharge and 
cough, in the absence of fever and swelling. Acute 
sinusitis should be considered when the duration 
of purulent nasal discharge exceeds 9 or 10 days, 
since rhinitis due to respiratory virus infection usually 
resolves without specific therapy before this time. In 
adults, acute sinusitis is diagnosed in the presence of 
purulent nasal discharge, facial pain, and headache with 
or without fever, lasting for more than 2-3 days. 
Although maxillary sinusitis is the most common form, 
ethnioidal, frontal and sphenoidal sinusitis also occur. 
Endoscopic examination is sometimes used in  
specialist centers for the diagnosis of acute sinusitis, but 
in general practice the diagnosis is based on history and 
clinical symptoms without specific culture from the 
sinus. In contrast, if the patient fails to respond to 
therapy, progresses, or manifests intracranial or orbital 
complications, adequate samples for microbiological 
culture should be taken immediately. Radiography is 
usually reserved for cases with complications, and 
computed tomography (CT) or magnetic resonance 
imaging (MRI) can reveal anatomic relationships. 
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Complications 
I~ivolvenient of the central nervous systeni, although 
rare, is a potential complication of acute sinusitis. 
Most conmionly it is caused by Stupliylococccrs unrens, 
a pathogen that is an otherwise uncommon cause of 
acute sinusitis but which is frequently involved in cases 
with intracranial complications. 
Etiology 
Similar pathogen? occur in both adults and children. 
The most common causes of acute sinusitis are Strepro- 
c o r m  pnenrrianiae, Hueniophilcrs ir$nenzue and Moruxella 
cuturrliulis. S tr i~ptorocc.~~ prieurnoriiue and H. i n ~ u e n z a a  
together account for approximately 75% of acute 
sinusitis cases, and Moruxella cuturrliulis for 5-10'X. It 
appears, however, that the prevalence of acute sinusitis 
due to Moraxella cutarrlzulis varies according to geographic 
location and age, whereas Streptocomrs pneirrizoniue and 
H .  inflcrenzae infections are ubiquitous. Acute sinusitis 
due to Sraphylorocrns a i r~ens  is  relatively uncommon, 
with a prevalence of approximately 5%, but Stuphylo- 
rocms uuwus should be considered the principal causative 
agent in those cases where septic complications are 
present. Group €3 streptococci are also occasional 
pathogens in acute sinusitis. In contrast, anaerobes 
are probably not causal pathogens and their role, if 
any, is unclear 131. The exception is acute sinusitis 
secondary to periodontal alveolitis in adults (acute 
maxillary sinusitis) where anaerobes are primary 
pathogens. Hospital-acquired acute sinusitis, following 
prolonged intranasal intubation, can be caused by a 
variety of Gram-positive and Gram-negative organisms 
that colonize the pharynx in intubated patients. 
Treatment 
Treatment of acute sinusitis is empirical and antibiotics 
should, therefore, be selected on the basis of known 
susceptibilities of the chief pathogens, Streptoconits 
przerrrnoniae and H .  inflctenzue. Clearly, the aim is to 
prescribe an antibiotic that is effective against both 
pathogens but Streptococrirs pnerimoniue and Stapkylocorrtrs 
unretLx should, nonetheless, be considered as the prin- 
cipal targets because the sequelae of inappropriate 
treatment are often more serious for these pathogens. 
Adults presenting with acute sinusitis with a 
duration of inore than 2-3 days, and children with 
symptoms lasting longer than 9 days, should be treated 
with antibiotic therapy. The length of antibiotic treat- 
ment is usually between 10 and 14 days. Children 
presenting with the more severe form of acute sinusitis 
often require hospital admission and treatment with 
parenteral antibiotics. 
It  appears that the incidence of penicillin-resistant 
pneumococcal itolates is greater in children than in 
adults, perhaps reflecting a greater use of antibiotics 
in children. It  should be noted that prieuniococcal 
resistance to all the commonly used drugs has been 
observed, with some strains being multiply resistant. 
Kesistance patterns vary according to geographic 
location, making it difficult to make generalized treat- 
ment recommendations. 
Penicillins 
Pneumococcal resistance to penicillin is now extremely 
high in  many countries, with prevalence rates of 
70-80%, in parts of South Asia and Hong Kong. In 
Scandinavian countries and the USA, the prevalence of 
resistance is much lower than this but is still a significant 
problem. Several eastern European countries have a 
considerable incidence of resistant strains. France and 
Spain have a prevalence of penicillin-resistant pneumo- 
cocci of40-50%. It is important to distinguish between 
low (MIC 0.1-1 mg/L) and high (MIC 22.0 mg/L) 
levels of resistance. Currently, in most countries, it 
is exceptional to find a Penicillin-resistant strain with 
an MIC > 4 mg/L. Petiicillin-reti?tant pneumococcal 
strains are frequently also resistant to other drugs 
traditionally used in pneuniococcal infection, e.g. oral 
cephalosporins, co-trimoxazole, tetracycline and macro- 
lides/azalides. For example, a recent study chowed that 
in Spain, 66% of penicillin-resistant pneumococci 
were multiply resistant 141. Although pneumococcal 
resistance is the principal concern, H .  itzfluenzur resist- 
ance is also a growing problem; in Europe, approxi- 
mately 15-20% of p-lactamase-producing strains of 
H .  ir!flirenzue are ampicillin resistant and these figures 
are higher in the USA (20-30%1) 131. 
Anioxycillin currently remains the most active 
oral p-lactam agent against pneumococci and has the 
advantage that the dose can be substantially increased 
in situations where higher drug doses may be required 
because of potential resistance. The addition of a p- 
lactamase inhibitor, wch as clavulanate, to aniox).cillin 
is, however, necessary because of the high prevalence 
of non-type B H. ir$uenzae strains in Europe and the 
USA that produce p-lactamase. Moreover, due to the 
almost universal production of p-lactamase, Moruxella 
cuturrldis is sensitive to amoxycillin/clavulanate but not 
to amoxycillin alone. Amoxycillin plus a p-lactamase 
inhibitor such as clavulanate is,  therefore, the current 
treatment of choice for acute sinusitis. 
Cep halosporins 
The increasing prevalence of penicillin-resistant 
pneumococci is a cause for concern, particularly as 
these strains will manifest some degree of resistance to 
other p-lactam antibiotics, including cephalosporins. 
At  present, however, prieuniococcal resistance to 
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cephalosporins such as cefotaxime or ceftriaxone 
(defined as MIC > 2  mg/L) appears to be relatively 
uncommon in most countries, with a prevalence 
of approximately 3-8%. Both cefuroxime and 
cefpodoxime appear to have good activity against 
intermediately resistant pneumococci. For example, in 
one randomized, double-blind study of 286 patients 
with acute maxillary sinusitis, cefpodoxime proved as 
effective as amoxycillin 161. Certain cephalosporins, 
such as cefuroxime and cefpodoxime, therefore, have a 
role as second-line treatment for acute sinusitis. 
Caution should be exercised in prescribing some 
cephalosporins, however, as cefaclor (even though 
widely prescribed) and cefiibuten have very high MICs 
predictive of low efficacy in acute sinusitis, and thus 
they cannot be recommended for this indication. 
Macroiides 
Many penicillin-resistant pneumococci are resistant to 
macrolides, with incidence rates ranging from 20% 
to >50% [7,8]. For example, in Spain, approximately 
20% of pneumococcal strains are resistant to macrolides, 
such as erythromycin, while in France, the prevalence 
is higher (close to 30%), and the percentages are greater 
among penicillin-resistant strains 191. In addition, con- 
trolled studies of clarithromycin and azithromycin 
suggest that this class of drug has little activity against 
H .  inJuenzae, the second most common cause of acute 
sinusitis [ 10,111. Macrolides may thus not provide 
optimal therapy for the initial management of sinusitis. 
Fiuoroquinoiones 
At the present time, acute sinusitis therapy is empirical: 
amoxycillin plus clavulanate provides broad, adequate 
coverage and is, therefore, the current treatment of 
choice. The future role of fluoroquinolones in this 
indication remains to be determined. Nonetheless, 
sparfloxacin has been shown to be effective, with com- 
parable efficacy (83% success rates) to cefuroxime in 
a double-blind niulticenter trial of 382 patients with 
acute sinusitis 1121. Ofloxacin treatment of 136 patients 
with acute or chronic sinusitis resulted in a cure rate of 
95% [13]. Similarly, studies with levofloxacin have 
shown clinical cure rates of 88-92% [14-161. 
CHRONIC SINUSITIS 
Definition and diagnosis 
Chronic sinusitis is a persistent, inflammatory disorder 
of the sinuses. Chronic sinusitis is predominantly a 
disease of adults and is one of the most frequent 
infections treated in the outpatient setting. Chronic 
sinusitis may present more subtly than the acute form 
and the diagnosis may be missed unless an appropriate 
history is taken [17]. The symptoms are non-specific 
and may be difficult to differentiate from other URTIs 
or an allergic rhinitis. Patients generally do not present 
with headache, facial pain or tooth pain but rather nasal 
obstruction, purulent oropharyngeal drainage, chronic 
cough, sore throat or halitosis. 
In contrast to acute sinusitis, microbiological culture 
and identification should routinely be performed in 
chronic sinusitus. Routine culture is not always current 
clinical practice, probably because of the difficulty 
of obtaining samples by puncture, but is strongly 
recommended because of the frequent polymicrobial 
origin of chronic sinusitis. Supplementary diagnostic 
procedures include endoscopy, radiography and CT. 
Endoscopy permits comprehensive examination and 
can confirm if conditions are surgically treatable. The 
most reliable radiographic findings are the presence of 
air-fluid levels and complete opacification of sinus 
cavities. CT is a highly sensitive and accurate technique 
for diagnosing sinusitis. However, as it is expensive to 
perform, its use is restricted to atypical cases [2]. 
Etiology 
In contrast to acute sinusitis, the etiology of chronic 
sinusitis is usually polymicrobial. The pathogens com- 
mon to acute sinusitis, namely Streptococcus pneumoniae 
and Staphylococcus aureus, are also found in the chronic 
form. In addition, anaerobes, enteric bacteria and 
Pseudomonas aeruginosa are often present. Anaerobes 
generally account for up to 25% of infections but 
different studies have yielded widely differing results 
[18,19]. In general, the etiology of chronic sinusitis is 
similar for adults and children. 
Treatment 
The approach to treatment of chronic sinusitis differs 
from that for acute disease because of the polymicrobial 
nature of the infection. Thus, empirical therapy is not 
appropriate and routine microbiological diagnosis both 
for aerobic and anaerobic bacteria should be under- 
taken. Treatment can, therefore, be targeted to the 
causal pathogens on an individual basis. Depending on 
the culture results, fluoroquinolones may be an appro- 
priate therapy. 
Clinical trial data have demonstrated the efficacy 
and tolerance for ofloxacin and ciprofloxacin in chronic 
sinusitis. In a 12-month study in 56 patients with 
chronic sinusitis given ciprofloxacin 500 mg twice daily 
for 9 days, rhinorrhea, which was the main outcome 
measure for efficacy, was cured in 85% of patients 
(46/54) and bacteria were eradicated in 90% of patients 
(27/30) with culture-confirmed sinusitis [20]. Legent 
et a1 compared ciprofloxacin 500 mg twice daily with 
amoxycillin/clavulanate 500 mg three times daily, both 
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for 9 days. in a double-blind, placebo-controlled study 
in 2.51 patients 1221. T h e  clinical cure and bacteriologic 
eradication rates were 59% versuc 51% and 89% versus 
9(J% for ciprofloxacin arid anioxycillin/clavLilanate, 
respcc tively. Geharino and Coheii studied the efficacy 
of ofloxacin 200 nig twice daily for 12 days in the 
treatment of  198 adult patients with chronic sinusitis in 
an open, outpatienti study 1221. Clinical improvement 
or  cure occurred in 94% of patients. T h e  spectruni 
of pathogens isolated included S r a p h y l o m m s  aiue i fJ ,  
hcrrdor?7orins nzn~~qiriora, Pvotcirs r 1 1  irnbilis, and H. ir$uevix(J, 
which were all sensitive t o  ofloxacin. 
T h e  efficacy of  fluoroyuinolones in chronic sinusitis 
could also have been predicted from the broad anti- 
microbial spectrum and the phariiiacokinetics of 
drugs i r i  this class. O f  151 bacterial strains isolated 
from adult patients with chronic sinusitis (Stayhylorocrur 
a~r~c~crs ,  Strcptocoaris prierrrrroniac, Ps'srirdorriorias nevugiriosn, 
H .  ir!flrrcrizne, arid various Enterobacteriaceae), 93% 
were susceptible to ciprofloxacin, 75% to ofloxacin and 
100?4 to sparfloxacin [ 2.11. Human pharrnacokinetic 
dat'i suggest that levofloxacin achieves concentrations in 
sinus fluid and tiswe that are comparable to  serum levels 
[?.I]. Likewise, sparfloxaciii has  been shown to achirve 
high concentrations in maxillary sinus iiiucosa follow- 
ing oral dosing of patients with chronic maxillary 
sinusitis [2J]. Siiiiilarly. ofloxacin and pefloxaciii c o ~ i -  
centrations in sinus tissue and fluid can exceed those in 
serum in caes  of  chronic sinusitis [21,26]. 
In general, the length of antibiotic treatment for 
chronic sinusitis is at least 3-1 weeks but, regardless of  
the treatment, a t  least an additional 3 days of therapy 
is 'idvised once symptoms have resolved. Although 
antimicrobial therapy can control the infection associated 
with chronic sinusitis, it rarely achieves cure because 
there is usually a n  underlying anatoniic or physiologic 
dcfrct ca~is ing poor drciinage, lack of  patency of thc 
sinus ostia and/or tissue edema. Supplementary treat- 
ment that may ease symptoms includes decongestants, 
local steroid therapy and saline douches. If sinusitis 
persists despite antibiotic therapy surgical intervention 
~ n n y  be required to re5toi-e sinus ventilation and to break 
the cycle ofinfection. In soiiie pediatric cases, however, 
high-dose pirentera1 antibiotic therapy for several weeks 
has achieved cure and negated the need for surgery, 
prcsumably because the high doses allow improvcd 
penetration to the site of infection. 
SINUSITIS IN THE IMMUNOCOMPROMISED HOST 
I n  the iiii~iiunocoinproinised host. i t  is often difficult 
to differentiate between acute and chronic sinusitis. I n  
most cases, patients will have a prior history of sinus 
problems and experience acute exacerbations when 
they become immunocoinproiiiised. I n  patients with 
HIV infection. Pserrdomorrns nerrdqirrosn sinusitis is 
relatively coninion and can occur in addition to or 
separate from pneumococcal infection, though other 
Gram-negative species, particularly KlcDsiella, fungi and 
mycobacteria. have also been isolated from sinus 
aspirates. Because of the possible multiple etiology, 
niicrobial culture and identification are obligatory so 
that treatment can be targeted ;it the particular causal 
pathogen(s). Fluoroquinolones are likely to prove useful 
for sinusitis in the iiiiiiiuiioco~iiproiiiised host wherevei- 
the etiology warrants their ~ l e c t i o i i .  
OTITIS MEDIA 
Otitis media is the most coninion bacterial infection in 
young children. with approximately 80'% of cases occur- 
ring in patients under 15 years old, the majority of 
which occur in patients less than 2 years old. Between 
1975 and 1990 in the USA, the diagnosis of otitis ~iiedia 
increased by approximately 150% 1271. Otitis media can 
result in important sequelae i n  the middle e x  and 
adjacent structiires such as cholesteatoma. hearing loss 
and, cilthough occurring rxely tod,iy, life-threatening 
intracrmial suppurative coniplications. 
ACUTE OTITIS MEDIA 
Definition and diagnosis 
Acute otitis media is characterized by accuniulation of 
pus in the middle ear .ind an inflamed t)mpanic 
membrane. I t  is almost exclusively J pediatric disease 
and i \  the most frequent single indication for 'inti- 
niicrobial treatment in children in the USA [28] .  By the 
age of 3 years, >80'%1 of children have had an episode 
of acute otitis media and > 40%) have experienced three 
or  more episodes 1291. I n  comliion with acute sinusitis. 
acute otitis media ~ i ~ ~ i a l l y  folloxvs on from viral 
respiratory infection (281. 
lliagnosis is established on the basis of  clinical 
syniptomatoloSy and physical findings. Lhgnostic signs 
&ire based on the appecirance and decrease in mobility 
of the tympanic niembrane together with symptoiiis 
of an ,icute illness lvhicli m ~ y  include rhinitis. cough. 
restlessness, irritabilip, fever, difficulty i n  feednig and 
earache. Surprisingly, earachc is only present in approxi- 
mately half of children \vith acute ot i t i$  media 1281. 
Microbial diagnosis is generally not necessary for making 
a therapeutic decision a id  should be reserved for 
recalcitrant cases and the iniiiiunoconipromised patient. 
Etiology 
T h e  main pathogens are identical to those in 
acute sinusitis, which are (in order of importance) 
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Streptococcus przeumoriiae, H.  influerizae and Moraxella 
catarrlzalis. Nonetheless, marked geographic variations 
occur. Depending on geographic location, the distri- 
bution is 20-40% for Streptococcus pneumoniae, 10-30%) 
for H .  injuenzae and 5-1596 for Moraxella catarrlzalis 
[2X]. In contrast, a study in Spain revealed a frequency 
of kforaxella catarrlialis of 0% in tympanocentesis 
saniples from 100 consecutive pediatric cases [30]. Other 
bacteria that occasionally cause acute otitis media are 
Pseudoinonas aerugiriosa, Staplzylococcus aureus, Strepto- 
coccus pyogerzes (group A P-hemolytic streptococci) and 
Clilarnydia spp. [31,32]. Although Staplzylococcus aureus 
and Pseirdomonar aertrginosa are often isolated, they are 
frequently contaminants or colonizers and are not 
responsible for the infection. 
Treatment 
Treatment of purulent acute otitis media consists of 
antibiotic therapy and is empirical in nature. The 
appropriate therapy should be selected on the basis 
of knowledge of the local principal pathogens and 
resistance patterns. With appropriate antimicrobial 
treatment, most patients with acute otitis media 
are significantly improved after 2-3 days. Persistent 
recurrent pain and/or fever indicate the need for either 
tympanocentesis/myringodectoniy to obtain a specimen 
for Gram-staining and culture, or selection of an alter- 
native antimicrobial, or both. 
In coniinon with acute sinusitis, antibiotic resistance 
is a growing probleni in otitis media, with decreasing 
susceptibility of Streptococcus pnetrrnoniae to penicillin 
and other p-lactam antibiotics, and increasing rates 
of P-lactamase-producing H .  inzrrenzae and Moraxella 
catarrlialis [33,34]. It  is now clear that resistance predicts 
bacteriologic failure and that about one-third of patients 
who fail bacteriologically will also fail clinically. Even 
intermediate levels of pneumococcal resistance to peni- 
cillin (MIC >0.1 nig/L, < 1 mg/L) are associated with 
bacteriologic failure [35]. Moreover, where penicillin 
resistance occurs, resistance at similar or, in some 
cases, even higher levels to cephalosporins is also being 
observed. 
The most commonly used drug for this indication 
is amoxycillin, with or without clavulanate. In many 
countries, the second most commonly used drug is 
cefaclor but several studies have shown it to be relatively 
ineffective [36]. Ceftriaxoiie is one of the most effective 
drugs for acute otitis media but the lack of an oral 
forniulation limits its use. As with acute sinusitis, 
inacrolides are probably not a good choice for this 
indication, as they appear to be generally ineffective 
.Igainst H. ii&wzae. At present, the role for fluoro- 
yuinolones in acute otitis media remains to be dernon- 
strated, especially in the pediatric field. 
CHRONIC SUPPURATIVE OTITIS MEDIA 
Definition and diagnosis 
Chronic suppurative otitis media is usually charac- 
terized by a polymicrobial infection often associated 
with an underlying anatomic or functional abnormality. 
Microbial culture and identification is advised because, 
although Pseudonionas aeruginosa is very often the 
causative organism (see below), it is still necessary to 
determine the antimicrobial susceptibility of the strain 
involved, as well as rule out other pathogens. 
Etiology 
The bacteriology of chronic, suppurative otitis media 
differs markedly from acute otitis media. The most 
commonly identified pathogens are Pseudoinonas aerirg- 
inosa (21-95% of cases), Staplzylococcus aureus (10-45%) 
and various Enterobacteriaceae (approximately 20%), 
including Protetrs species [23]. Of  these, Pseudomorzas 
aerrrginosa is the most comnion cause of childhood 
chronic, suppurative otitis. Anaerobes have been reported 
in 30-60% of cases although their exact role in the 
pathogenesis of chronic, suppurative otitis media is 
uncertain [3]. 
Treatment 
Because of the high prevalence of Pseudouzorzas aeruginosa 
infection, common treatnient options are somewhat 
different from those for chronic sinusitis. Current treat- 
ment options include ciprofloxacin and ceftazidinie, 
usually administered in conjunction with daily ear 
hygiene. 
It  has recently been demonstrated that topical 
treatment alone with fluoroquinolones is an effective 
treatment for chronic, suppurative otitis niedia and 
successfully dries the ear, allowing surgery to be 
performed at a later date to correct the underlying 
problem. Thus, a multicenter, open-label study of 109 
adults with chronic, suppurative otitis media, prin- 
cipally caused by Stapliylococcus aureus (28%), Pseirdo- 
~ i o i z a s  aeru'qinosa (23%) and Proteus ~ i r a b i l i s  (1 I%), 
demonstrated 92% clinical response (ear successfully 
dried) and 96% bacteriologic cure following treatment 
with 0.3% ofloxacin given twice daily for 10 days [37]. 
Similar studies have recently been carried out in 
Thailand and China [38-401. 
Oral fluoroquinolones are also clearly effective for 
chronic, suppurative otitis media. The majority of otitis 
media pathogens are susceptible to fluoroquinolones, 
with one study showing 95% of strains to be suscep- 
tible to ciprofloxacin, 73% to ofloxacin and 85%) to 
sparfloxacin [23]. Although one animal study has 
shown certain fluoroquinolone concentrations in the 
middle ear to be approximately 50% of serum levels, a 
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clinical study of patients with chronic otitis media 
demonstrated bone and cartilage ofloxacin concen- 
trations to exceed the serum level [41]. Moreover, in 
the same study of 215 patients with chronic otitis 
media, treatment with oral ofloxacin resulted in a 94% 
clinical cure/improvenient rate [22]. Similarly, a study 
of levofloxacin in Japan demonstrated equivalent drug 
levels in the middle ear and serum [42]. In addition, 
in a study of 21 children with chronic suppurative 
otitis media without cholesteatoma, treatment with 
oral ciprofloxacin 30 mg/kg per day for a mean of 17 
days was shown to be effective and well tolerated 1431. 
In addition to antibiotic therapy, common measures 
used to prevent effusion and recurrence include tym- 
panocentesis, myringotomy with the insertion of a 
tyinpanostomy tube and adenoidectomy. Surgery 
should only be considered after the patient has been 
observed and inanaged for a period of at least 3 months 
and with documented bilateral hearing loss of >20 dB. 
OTITIS MEDIA IN THE IMMUNOCOMPROMISED HOST 
As with sinusitis in the immunocornpromised host, 
niicrobiological culture should be routine to allow 
treatment to be tailored to the specific pathogen(s). 
PHARY NGlTlS 
Definition and diagnosis 
Pharyngitis is an inflammatory syndrome of the 
oropharynx predominantly resulting from local in- 
fection, or, less coninionly, from systeniic infection, 
allergy, or toxins. It  is one of the most conniion 
presenting symptoms, accounting for approximately 1%) 
of physician visits every year. Pharyngitis is extremely 
comnion in all age groups, with a peak incidence 
between 5 and 15 years of age. 
Symptoms of 5treptococcal pharyngitic include 
malaise, odynophagia, headache, anorexia, abdominal 
pain and, often, moderate-to-high fever. Fever is 
the most coninion symptom i n  children. Associated 
physical findings. in sonit' patients, include a iioii- 
adherent pharyngeal exudate, erythema, petechiae, 
'doughnut lesions' (a raised heniorrhagic area with 
a yellow exudative center), lymphoid hypertrophy, 
cough and rhinorrhea. Laboratory evaluation correlates 
leukocyto5is or a systemic white blood cell count 
> 8500 with streptococcal infection. Other diagnostic 
techniques are rapid antigen-detection tests (ADTs) 
and serologic tests [44]. 
Etiology 
The predominant c ~ u s e  of bacterial pharyngitis corn- 
prises group A p-heniolytic streptococci (Streproiocriiz 
pyogenes). Examples of other bacterial pathogens that 
may occasionally cause pharyngitis include group C 
and G P-hemolytic streptococci, Mycoplasr~in przetrrmrtiae, 
H .  ir$irenzae, Clzlamydia p m m o r z i a e  and C o q w b n f -  
terium lzaemolytirum [44,45]. Viral pathogens, such as 
coxsackie viruses, Epstein-Barr virus and herpes virus, 
are responsible for the majority of cases. 
Treatment 
The standard treatment for pharyngitis is penicillin, 
either oral penicillin VK or intramuscular penicillin 
G for 10 days. Despite 50 years of penicillin use 
in pharyngitis, drug resistance does not appear to be 
a significant problem. For patients allergic to peni- 
cillin, cephalosporins provide a suitable alternative; 
for example, cefuroxinie has shown efficacy in this 
indication [46]. Ampicillin and anioxycillin may also be 
used but offer no significant advantages over penicillin. 
Fluoroquinolones are not appropriate for the empirical 
treatment of pharyngitis at present, because the avail- 
able agents are more effective against the principal 
pathogen, Streptococcus pyo,per ,  and currently, fluoro- 
quinolones are not licensed for pediatric use. Antibiotic 
treatment of pharyngitis usually produces symptomatic 
improvement within 1-3 days, with reniission of fever 
within 24 h and decreased symptom and suppurative 
sequelae within 3 days. 
CARRIER STATES 
Certain potential pathogens can be found in the 
pharynx in the absence of syiiiptoiiiolog.?.: I t  is 
known that fluoroquinolones can eradicate L"\iisseria 
rrzeninfitidis from the pharynx and such prophylaxis 
would be warranted in certain situations, e.g. to treat 
close contacts during an attack of meningococcal 
disease. The potential of new, respiratory fluoro- 
quinolones, with their more favorable pharniacokinetic 
profiles, to eradicate colonizing Stwptorocc-its prwrrr/roniac~ 
from the pharynx should be explored. 
CONCLUSIONS 
URTIF represent a significant cause of iiiorbidity in 
both adults and children and a significant challenge 
because of the increasing problem of  antibiotic resist- 
ance among the three major UKTI pathogens, Strepto- 
r0ciu.i yiieumorriae, H .  ii!flueiizae and Morasellu catarvlzalis. 
Both acute sinusitis and acute otitis media are generally 
benign conditions that arc' most often succersfully treated 
with empirical therapy, such as anioxycillin plus a p- 
Lctama5e inhibitor, such as clavulanate. Some fluoro- 
quinolones have been found to be effective, but their 
use as first-line Agents ic  not recommended at this time. 
G a r a u  e t  a l :  F l u o r o q u i n o l o n e  t r e a t m e n t  of  URTls 
In contrast, chronic sinwitis, chronic suppurative 
otitis media and URTI in the immunoconipromised 
host warrant identification of the specific pdthogen in 
order to select the most appropriate therapy. The newer 
fluoroquinolones, with their broader coverage of the 
major respiratory pathogens, may represent a useful 
therapeutic option for chronic sinusitis and chronic 
otitis media. Moreover, while current therapies pro- 
vide adequate coverage of acute sinusitis and acute 
otitis media, if high-level penicillin resistance (MIC 
> 4 mg/L) eventually becornes widespread among 
pneumococci, the use of fluoroquinolones in these 
indications will warrant further consideration. Further 
pharmacokinetic and clinical efficacy trials are needed 
to determine the optimal use of fluoroquinolones in 
the field of URTIs. 
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